The Challenges of Developing a Safe and Effective COVID-19 Vaccine

By Mr. Neeraj Mehta, CEO, Immunifyme

COVID-19 which is caused by the virus named SARS-COV-2, originated from China and quickly spread across the globe. WHO recognized it as a Pandemic which has till today infected 15.2 million people worldwide and more than 620 thousand deaths. In India it is spreading wider and till now about 1.24 million people are infected and nearly 30 thousand people have lost their lives.

It is a dreaded disease and the whole world is looking for a vaccine to treat the COVID-19 effectively and control the spread of the disease. While many companies are in the race to produce a vaccine, few have already gone into various Phases of human trials. Moderna's mRNA-1273 and Oxford-AstraZeneca's Covid vaccine are ahead and have proven the safety and efficacy of the vaccine.

So now that we know, the vaccines are definitely on the way, the world will face a different kind of challenges. 

Few of the challenges which I see are:

1. Avoiding counterfeited vaccines 

Fake Vaccines! Yes, COVID-19 is a dreaded pandemic and everyone is looking forward for a vaccine. Thanks to Serum Institute of India and Adar Poonawalla that we have already started the production of COVID-19 vaccine in the name of Covishield for India and the world.

2. Vaccine Distribution

Covishield is not a Routine Vaccine: The world will need billions of doses to be manufactured in order for the vaccine to be available in all parts of the World, thankfully Serum Institute of India is one of the only few companies in the world to have the capability to manufacture this volume of doses. GAVI too has tie-up with UPS. UPS has committed a US$ 3 million in new funding and in-kind logistics support spanning two years, provided by UPS and The UPS Foundation to Gavi. This initiative will help COVID-19 vaccine's equitable and timely distribution. However, India will still need its own logistics in order for the vaccine to reach to everyone. We must ensure it is accessible to each person in India.

3. Surveillance during Vaccination and monitoring and follow-up for upcoming doses

Monitoring of people who would have received the vaccine: This is extremely crucial for us to monitor people who would have received the vaccine, in order to ensure they also receive the follow up dose and how are they doing in the long run after receiving the vaccine.

While it is a great thing that vaccine will be available soon, but we should be prepared for a long wait as well. The initial supplies will be extremely limited and the frontline health-care professionals will get the first access followed by those people who are vulnerable to serious illness. To make this vaccine reach each and everyone, India will have to work hand in hand with other nations.

Covestro and Google Cooperate on Research for Novel Computer Technology

Benefits

* How Quantum Computing Can Benefit Chemistry

* Milestone in digital research and development

* Expand innovation leadership with quantum computing

Significantly less time, less use of resources, more efficient and environmentally friendly processes, completely new materials – this is the future potential of the novel technology Quantum Computing in research and development for the chemical industry. In order to achieve long-term innovation leadership in this still developing field of digital chemistry, Covestro builds up resources and expands partnerships. With so-called quantum computing, the materials manufacturer is going one step further to investigate new possibilities in the field of chemical simulations. Therefore, Covestro and Google have signed a research partnership agreement. The current research focuses on the development of fundamental algorithms, while the future vision is to solve certain complex simulations in a fraction of the time compared to classical computers.

“Quantum computing opens up groundbreaking new perspectives for our industry. We therefore want to invest specifically in the further development of this technology and build up expertise”, said Dr. Markus Steilemann, CEO of Covestro. “The partnership with Google gives us the opportunity to do so and is so far unique in the chemical industry.”

Quantum Computing opens up new dimensions

Covestro has already been investing extensively in digital research and development for around three years. The novel quantum computing is another important milestone in the search for new, digitized research processes. This forward-looking computer technology is the key to knowledge that is needed, for example, to successfully advance the circular economy. With the help of quantum computing, details of highly complex chemical reaction processes can be digitally simulated and evaluated in a very short time.

Hartmut Neven, head of the Google AI Quantum group states: “We are advancing quantum computing by developing quantum processors and novel quantum algorithms to help industry researcher partners solve problems. We are looking forward to the collaboration with the very strong team of scientists at Covestro.”

Quantum computing will help Google to develop the innovations of tomorrow, including AI. That’s why the company is committed to building dedicated quantum hardware and software today.

Quantum computing is a new paradigm that will play a big role in accelerating tasks for new computing capabilities. Google wants to offer researchers and developers access to open source frameworks and computing power that can operate beyond classical capabilities.

With quantum computing, Covestro intends to build on the success of previous investments and further deepen its global competencies in computational chemistry. In the long term, the technology can go far beyond the possibilities of high-performance computing. With the expansion of a classic high-performance computer at the Leverkusen site for computer simulations and a new, global platform for research data for more than a year, Covestro has been tapping into the value-added potential that the digital transformation of the chemical industry is opening up.

20200702-Covestro-Google-Quantum-en

Covestro and Google cooperate on research how quantum computing can benefit chemistry

Access to technology and know-how

The partnership on quantum computing between Google and Covestro forms the basis for joint scientific cooperation. The main goal is the further development of quantum computing technology and how it can be used to solve chemical problems in the future. Google provides the hardware and access to its technology experts. Thus, Covestro takes a pioneering role in digital research and development to test and further develop the new methods of quantum computing for the chemical industry.

About Covestro:

With 2019 sales of EUR 12.4 billion, Covestro is among the world’s largest polymer companies. Business activities are focused on the manufacture of high-tech polymer materials and the development of innovative solutions for products used in many areas of daily life. The main segments served are the automotive, construction, wood processing and furniture, and electrical and electronics industries. Other sectors include sports and leisure, cosmetics, health and the chemical industry itself. Covestro has 30 production sites worldwide and employs approximately 17,200 people (calculated as full-time equivalents) at the end of 2019.

Jyothy Labs Unveils #VocalforLocal Television Advertisement Campaign Supporting Aatmanirbhar Bharat

Jyothy Labs Limited (JLL), one of the leading Indian FMCG companies launched a brand new television campaign today in support of the #Vocalforlocal appeal made by the Honourable Prime Minister Shri Narendra Modi. The film narrates the journey of the company’s legacy since 1983 through a beautifully scripted song that describes the ethos and values of the company.

The launch comes at a time when the entire nation is witnessing an emotion of patriotism and self-reliance. The campaign focusses on the centricity of Jyothy Labs’ evolution and functioning being driven by ‘Bharat’. It depicts the joy and happiness of being a true Indian homegrown company serving its consumers through its various innovative products across the nation.

Expressing delight on the launch, Ms. Jyothy MR, Managing Director, Jyothy Labs Limited said “With a soul that reflects India for all intents and purposes, Jyothy Labs hereby pledges strong support to the ‘Vocal for Local’ initiative made by our honourable Prime Minister Shri Narendra Modi Ji. In the last 37 years of our existence we have thought, worked and served as an Indian keeping our nation and citizens at the forefront. Our single most important objective since inception was to contribute in nation building by serving the discerning consumer with innovative products that not only fulfils a need but become life changing solutions. With a new Television campaign supporting the Vocal for Local initiative, we want to reiterate our intentions of being ‘‘vocal about local’ products and help them become global.”

Supporting the Vocal for Local initiative and to become a part of ‘ATMANIRBHAR BHARAT Abhiyan’, Jyothy Labs started the campaign through BTL activities in May 2020, followed by Print ads in national dailies showcasing its ‘Made in India’ and ‘Made for India’ products. The TVC will furthermore propel its strong support for the VFL initiative and also strengthen its connect with the Indian consumers.

TVC Link: https://www.youtube.com/watch?v=ykoQFTpKYj0

About Jyothy Labs:

Jyothy Labs Ltd (JLL), one of the leading Indian FMCG companies was founded in 1983 by Mr. M P Ramachandran. Over the years the company has evolved from a single product proprietary firm into a multi brand, BSE & NSE listed company involved in the manufacturing and marketing of products in Fabric Care, Home Care, Personal Care and Dishwash categories.

The companys’ power brands includes Ujala, Exo, Maxo, Margo, Henko and Pril, The company is also engaged into service sector in organized laundry to provide “World class laundry at affordable price” through its subsidiary ‘Jyothy Fabricare Services Limited’.

Signify Invests to Broaden its UV-C Lighting Portfolio to Meet the Growing Demand for Disinfection

Expands Portfolio

* Launches 12 families of UV-C-based products for professional markets

* Acquires GLA to complement its portfolio with luminaires for upper-room air disinfection

* Increases its UV-C light source production capacity by a factor 8 this year

Signify, the world leader in lighting, is increasing its UV-C lighting production capacity and expanding its UV-C product portfolio to include 12 new families of UV-C based products for the professional segment. The company is leveraging more than 35 years of expertise in UV-C lighting to address the growing global need for the disinfection of air, surfaces and objects.

By increasing capacity and broadening the UV-C portfolio, Signify is helping keep people safe in a world that’s adjusting to a new normal. Its UV-C lighting is well-proven and trusted as an effective disinfectant. This was recently validated in a laboratory test by Boston University, showing that Signify’s UV-C light sources inactivate the virus that causes COVID-19 in a matter of seconds. This is crucial as it comes at a time when organizations are seeking ways to continue operations and provide service in a safe environment.

Signify’s new UV-C product range includes luminaires and chambers for a wide variety of professional applications. “We have introduced 12 families of UV-C lighting fixtures specifically designed to disinfect air, surfaces and objects. These products target different customer segments ranging from offices, schools, gyms, retail stores, warehouses, as well as on public transport,” said Harsh Chitale, Leader of Signify’s Digital Solutions Division.

“The ongoing pandemic is unprecedented in its scale and impact on society and impacts millions of lives across the globe. With our latest UV-C product range that has been validated to effectively inactivate the virus that causes COVID-19, we hope to contain the spread of this virus in India. The new UV-C lighting fixtures are designed for use in various aspects of public life as people begin to step out again and return to their workplaces. We are actively working towards creating solutions for home consumers as well.” said Sumit Joshi, Vice Chairman and Managing Director, Signify Innovations India Limited.

Part of the range are UV-C fixtures which are ideal for the deep disinfection of surfaces in offices, schools and restrooms. They are equipped with sensors and controls to ensure that they only operate when people and animals aren’t present as UV-C radiations can damage the skin and eyes. Other products include mobile, freestanding UV-C luminaires that can be wheeled into a hotel room or used to disinfect surfaces on public transport such as buses and trains.

For the disinfection of objects, Signify launches a range of safe and quick-to-use UV-C disinfection chambers. These chambers are used in offices and municipal buildings to disinfect visitor tags, phones, bags, laptops and wallets in a matter of seconds. In stores they’re ideal for disinfecting returned items, glasses or clothes tried on in a changing room.

UV-C fixtures can also be used inside surface disinfection tunnels. In North America a large retailer is piloting a UV-C tunnel for disinfecting shopping trolleys. In India, a hotel plans to use a Signify UV-C tunnel for disinfecting guests’ bags at check-in.

To complement its portfolio, Signify recently acquired the assets of Germicidal Lamps & Applications (GLA), a small, Netherlands-based company with extensive expertise in UV-C disinfection solutions. The deal includes GLA’s upper-room UV-C air disinfection portfolio as well as deep application knowledge. 

“The assets and know-how acquired from GLA will help us to accelerate the development of our roadmap of UV-C based upper-room air disinfection systems. We plan to make these products available across the world soon,” said Paul Peeters, Leader of Signify’s Digital Solutions Europe.

The upper-room air disinfection luminaires can be used with people in the room, as they are installed at a height which, in combination with shielding and optics, prevents exposure to the UV-C light source. Air in the upper part of the room is constantly disinfected using UV-C irradiation and natural convection of airflow in the room. This makes these perfect for use in schools, offices, gyms, retail outlets and other high-contact areas

For more than 35 years, Signify has been at the forefront of UV technology, and has a proven track record of innovation in UV-C lighting. Signify’s UV-C lighting is designed, installed, and used according to the product-specific safety instructions, and manufactured using well-controlled industrial processes.

Abbott to Supply More Than a Million Tests of IgG Lab-Based Antibody Tests to India

Medical Milestone

* Abbott's SARS-CoV-2 IgG test can be used for highly-reliable, large-scale antibody testing, in line with the ICMR recommendation for the use of IgG CLIA (Chemiluminescence immunoassay) tests

* Abbott's antibody test is being deployed by many hospitals and labs across the country to understand the extent of infection in population exposed, as well as for surveying high risk or vulnerable populations *

* Test demonstrated reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days or more after symptoms started 

Abbott announced has that it has begun supply of its laboratory-based serology blood test for the detection of the antibody, IgG (Immunoglobulin G), that identifies if a person has had the novel coronavirus (COVID-19). Abbott has the capacity to provide millions of tests to India and is already in the process of delivering antibody tests to leading government and private hospitals and labs in Maharashtra, Delhi, West Bengal, Uttar Pradesh, Jammu & Kashmir and Gujarat.

"Abbott is pleased to contribute to ICMR’s COVID-19 antibody testing strategy to use IgG CLIA antibody tests. Abbott’s recently launched SARS-CoV-2 IgG test can be used to understand the spread of transmission in high risk populations such as healthcare workers, immune-compromised individuals, frontline workers, or those in containment zones. These tests also provide valuable information to the public health officials about the spread in asymptomatic cases, helping us assess the impact of our public health efforts now and guide our COVID-19 response moving forward,” said Narendra Varde, General Manager and Country Head at Abbott’s diagnostics business in India.

Mumbai’s Hinduja hospital was one of the first hospitals to evaluate the test in India. Dr. Tester F. Asha Vaid, Chief of Labs (Admn), Director Lab Research at Hinduja Hospital and Medical Research Centre, Mumbai, said, “This test is useful to clinicians and the community – our initial testing has yielded specific results for patients who were RT-PCR positive for COVID-19.”

Dr. Jayanthi Shastri, Professor & Head Microbiology, Kasturba Gandhi Hospital for Infectious Diseases in Mumbai said, “For a city like Mumbai, it’s critical to assess the level of exposure of population in the community, which can be done ward-wise, guiding authorities on re-assessing containment strategies. The test gains significant relevance in high-risk populations such as front line and healthcare workers, where outcomes will enable us in understanding contagiousness of COVID-19.”

Dr. Ujjwayini Ray MD (AIIMS), Consultant Microbiologist, Apollo Gleneagles Hospitals, Kolkata said, “We have found that patients who have clinically recovered or are on path of recovery have developed significant levels of IgG antibody against COVID-19. The IgG assay could be included in the discharge policy of hospitalised COVID-19 patients.”

Abbott's SARS-CoV-2 IgG test specifically identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered. The test is used on the ARCHITECT i1000SR and i2000SR laboratory instruments**, which are installed in hospitals or laboratories throughout India and can run up to 100-200 tests per hour to help with reliable antibody testing during the pandemic.  Independent researchers** found the test to have 99.9% specificity and 100% sensitivity for patients tested 17 days or more after symptoms began.***

Abbott designed its test to detect the IgG antibody specifically as it can better help physicians determine recovery from infection, versus looking at a combination of antibodies. Abbott is also developing an IgM antibody test.

About Abbott's Diagnostics Leadership

Abbott has long been a global leader in infectious disease testing, including the development of the first HIV test. The company created a Global Surveillance Program 25 years ago to monitor HIV and hepatitis viruses and identify mutations to ensure the company's tests remain up to date. Abbott also has a long-standing discovery program that identifies new or unknown pathogens and develops tests to address these new threats.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries. In India, Abbott was established in 1910, and is one of the country's oldest and most admired healthcare companies. With over 12,000 employees in the country, Abbott in India is helping to meet the healthcare needs of consumers, patients and doctors throughout urban and rural India.

Can supercomputers unravel universe's secrets?

Scientists are using the world's fastest supercomputer to model origins of the unseen universe including dark energy. Understanding dark energy is the number one issue in explaining the universe, according to Salman Habib of the Laboratory's Nuclear and Particle Physics, Astrophysics and Cosmology Group.

Even though it's looking at only a small segment of the 'accessible' universe, Habib's 'Roadrunner Universe' model requires a petascale computer because like the universe, it's very large, reports ANI. The model's basic unit is a particle with a mass of approximately one billion suns (in order to sample galaxies with masses of about a trillion suns) and it includes more than 64 billion of those particles.

The model is one of the largest simulations of the distribution of matter in the universe, and aims to look at galaxy-scale mass concentrations above and beyond quantities seen in state-of-the-art sky surveys.

According to Habib, as the universe is expanding and at the same time accelerating, either there is a huge gap in our understanding of physics, or there is a strange new form of matter that dominates the universe - 'dark energy' - making up about 70 percent of it. "In addition, there is five times more of an unknown 'dark matter' than there is ordinary matter in the universe, and we know it's there from many different observations, most spectacularly, we've seen it bend light in pictures from the Hubble Space Telescope, but its origin is also not understood," he added.

The Roadrunner Universe model relies on a hierarchical grid or particle algorithm that matches the physical aspects of the simulation to the hybrid architecture of Roadrunner. Habib and his team wrote an entirely new computer code that aggressively exploits Roadrunner's hybrid architecture and makes full use of the PowerXCell 8i computational accelerators.

Agencies

SAP Unviels Co-Innovation Lab in Bangalore

SAP AG formally launched its Co-Innovation Lab in Bangalore, the third such lab in the world by the company. The lab that started its operation in October last year, joins the league of similar labs in Palo Alto and Tokyo. "The main goal of this lab is to create a platform for collaboration between SAP and its customers and partners on solutions to different challenges in the industry", said Satyajit Singh Mecker, Senior Vice President, Global Ecosystem and Partner Group.

The SAP Co-Innovation Lab hosts a simulated heterogeneous datacenter, integrating hardware and software from SAP and other participating sponsors. "This lab is not like a R&D lab, but it is a real lab, where partners and customers can solve their problems by collaboration", said Satyajit.

Wipro Technologies, a SAP partner, was one of the first to benefit from this SAP initiative. An Insurance Claims Analytics solution was developed by Wipro by working on a platform that was developed in the SAP Co-Innovation Lab. Some of the other partners associated with the lab include Cisco, HP and Intel.

SAP India that now has over 3,800 customers with 2,900 SMEs in the list, wants to tap the potential in the Indian market by this collaborative effort. "India, especially Bangalore has been a region that has seen explosive growth and the global meltdown has not diminished its stature in the global market", said Dr. Axel Henning Saleck, Vice President and Head of the Global SAP Co-Innovation Labs.

"In 2006, SAP had announced a total investment of one billion dollar in India over 5 years and establishment of this lab is part of the investment", said Satyajit. According to Satyajit, the company sees tremendous potential in the Indian market in segments like information technology, engineering, construction, chemicals and automotive. "The current challenge that we see in India is to maintain a balance between customers and partners and keep the focus right", added Satyajit.

Agencies